

Halozyme Therapeutics

[View the current Halozyme Therapeutics Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/23804-Halozyme+Therapeutics.html)

(<http://www.bioportfolio.com/bi corporate/23804-Halozyme+Therapeutics.html>)

Contact Details:

Tel: 858.794.8889

Fax:

Email: dramsay@halozyme.com

Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's first hyaluronidase enzyme, recombinant human PH20 or rHuPH20, is the platform for three different products, including a medical device, a drug enhancement agent, and a therapeutic biologic. The company's initial products are being developed to offer safer and purer alternatives to existing slaughterhouse-derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme's highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine

Recent Publications by Halozyme Therapeutics:



- [Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase.](#)
*BACKGROUND: This phase 1 study investigated the pharmacokinetics (PK) and...*18th September, 2009
Halozyme Therapeutics, Inc., San Diego, California 92121, USA.- *Diabetes Technol Ther.* 2009 Jun;11(6):345-52. ([DOI Direct Link](#))
- [Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: a double-blind, placebo-controlled clinical trial.](#)
*Animal-extracted injectable hyaluronidases have been used safely for more...*8th January, 2008
Halozyme Therapeutics- *J Infus Nurs.* 2007 Sep-Oct;30(5):293-9. ([DOI Direct Link](#))
- [Recombinant human hyaluronidase \(rHuPH20\): an enabling platform for subcutaneous drug and fluid administration.](#)
*The extracellular matrix is a significant barrier to the effective...*19th September, 2007
Halozyme Therapeutics, Inc., 11588 Sorrento Valley Road, San Diego, CA- *Expert Opin Drug Deliv.*

2007 Jul;4(4):427-40. ([DOI Direct Link](#))

- [A recombinant human enzyme for enhanced interstitial transport of therapeutics.](#)

Subcutaneously injected therapeutics must pass through the interstitial... 20th October, 2006

Halozyme Therapeutics, San Diego, CA 92121, USA.- J Control Release. 2006 Aug 28;114(2):230-41.

Epub 2006 Jun 7. ([DOI Direct Link](#))

Press Releases on Halozyme Therapeutics:

Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal	20th November, 2009	Cornerstone Therapeutics Inc.	CARY, N.C., Nov. 20 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products
Reportlinker Adds Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to Drive Growth	20th November, 2009	Reportlinker	NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to
Cell Therapeutics Wins Federal Appeal to Pursue \$22.8 Million Claim Against The Lash Group	20th November, 2009	Cell Therapeutics, Inc.	SEATTLE, Nov. 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Ninth Circuit Court of Appeals reversed a U.S. District Court order and ruled
Monogram Energy, Inc. Acquires Triad Therapeutics, Inc.	19th November, 2009	Monogram Energy, Inc.	FAIRFIELD, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Monogram Energy, Inc. ("Monogram") (Pink Sheets: MGRN) announced today that it had completed the acquisition of Triad Therapeutics, Inc. (

[Quark Reports Progress of siRNA Clinical Programs: 300 Patients Dosed With Quark Pharmaceuticals's siRNA Drugs In Multiple Fully Enrolled Clinical Trials](#)

19th November, 2009 Quark Pharmaceuticals, Inc.

-- Pfizer Inc., which licenses PF-4523655 from Quark, has completed enrollment in a Phase 2 study of PF-4523655 in patients with diabetic macular edema (DME). PF-4523655 is

BioNews Results for Halozyme Therapeutics



- [ProMetic Life Sciences and Halozyme sign supply agreement](#)
Individual.com: Nov 11 2009 4:27PM Matching: halozyme therapeutics
- [Halozyme reports encouraging results from insulin variability study](#)
Pharmacy Choice: Nov 11 2009 12:59AM Matching: halozyme therapeutics
- [Halozyme Study Results Demonstrate Significantly Less Absorption Variability for Insulin Lispro Administered w](#)
Pharma Live: Nov 10 2009 9:38PM Matching: halozyme therapeutics
- [Halozyme reports encouraging results from insulin variability study](#)
Individual.com: Nov 10 2009 6:54PM Matching: halozyme therapeutics
- [ProMetic and Halozyme Enter Into Long-Term Supply Agreement](#)
Therapeutics Daily: Nov 9 2009 12:36PM Matching: halozyme therapeutics
- [ProMetic and Halozyme Enter Into Long-Term Supply Agreement](#)
Genetic Engineering News: Nov 9 2009 11:46AM Matching: halozyme therapeutics
- [Halozyme Study Results Demonstrate Significantly Less Absorption Variability for Insulin Lispro Administered w](#)
Cafepharm: Nov 9 2009 4:55PM Matching: halozyme therapeutics
- [ProMetic and Halozyme Enter Into Long-Term Supply Agreement](#)
Individual.com: Nov 9 2009 1:11PM Matching: halozyme therapeutics
- [ProMetic and Halozyme Enter Into Long-Term Supply Agreement](#)
Individual.com: Nov 9 2009 1:11PM Matching: halozyme therapeutics
- [Halozyme Study Results Demonstrate Significantly Less Absorption Variability For Insulin Lispro Administered W](#)
Medical News Today: Nov 9 2009 12:46PM Matching: halozyme therapeutics
- [Halozyme Study Results Demonstrate Significantly Less Absorption Variability for Insulin Lispro Administered w](#)
Houston Chronicle: Nov 8 2009 9:41PM Matching: halozyme therapeutics
- [Halozyme Study Results Demonstrate Significantly Less Absorption Variability for Insulin Lispro Administered w](#)
Freshnews.com: Nov 7 2009 3:13AM Matching: halozyme therapeutics
- [Halozyme Therapeutics announces results of its insulin variability study](#)
News-Medical.Net: Nov 7 2009 7:13AM Matching: halozyme therapeutics
- [Halozyme Says Study Results Demonstrate Less Absorption Variability For Insulin Lispro Administered With PH20](#)
RTTNews.com: Nov 7 2009 2:30AM Matching: halozyme therapeutics
- [Halozyme Study Results Demonstrate Significantly Less Absorption Variability for Insulin Lispro Administered w](#)
Stockhouse Canada: Nov 7 2009 12:51PM Matching: halozyme therapeutics



- [Phase II PK Study With Humalog and Humulin R With and Without rHuPH20 in T1DM](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

